Teriparatide (pth 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women
Journal of Bone and Mineral Research, 01/14/2014Yu EW, et al.
The authors studied the impact of long–term daily teriparatide (PTH 1–34) treatment on cells of the hematopoietic lineage in postmenopausal women. Twenty–three postmenopausal women at high risk of fracture received teriparatide 20 mcg SC daily for 24 months as part of a prospective longitudinal trial. Daily teriparatide treatment for osteoporosis increases circulating HSCs by 3 to 6 months in postmenopausal women. This may represent a proliferation of marrow HSCs or increased peripheral HSC mobilization. This clinical study establishes the importance of PTH in the regulation of the HSC niche within humans.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.